Merck AI Strategy: A $1 Billion Bet on AI Agents Across the Company
How Merck uses AI on its own work: a Google Cloud deal worth up to $1 billion, five CEO-sponsored programs and an AI platform used by 80% of staff. Updated November 2026.
Prescription medicines, vaccines and animal health products, known as MSD outside the United States and Canada
Merck has no standalone AI strategy document. Its approach comes from its April 2026 Google Cloud announcement, company stories and executive interviews.
Read the company sourceWhere Merck Is Going with AI
Merck is putting AI agents into every part of the company, backed by a Google Cloud deal worth up to $1 billion. The multiyear partnership, announced in April 2026, deploys an agentic platform across research, manufacturing, commercial and corporate functions. Merck has no standalone AI strategy document, so this profile draws on that announcement and executive interviews.
The aim is to change how work gets done at scale. Dave Williams, then Chief Information and Digital Officer, said: “AI agents and generative tools will help our teams around the world reimagine processes at scale.” Gaurav Gupta took over the role in September 2026.
The CEO sponsors five lighthouse programs. Williams told diginomica in April 2026 that the programs are all personally sponsored by CEO Rob Davis. He said: “The whole company is going to know these five, and Google is our partner on all of them.”
The focus has five parts, which Merck described in a January 2026 company story.
- Drug discovery: two AI foundation models for drug targets, molecular design and early testing of small molecules
- Clinical trials: AI for site selection, patient matching and retention
- Manufacturing: supply chain risk assessments in under 30 minutes and computer vision that inspects vaccine vials and syringes
- Commercial: AI across content creation and review, plus a chatbot that supports field representatives
- Corporate functions: AI-powered automation to improve productivity
What It Takes: A Partner Platform, Broad Use and Human Review
Merck already runs its own AI platform at scale. Merck said in January 2026 that more than 80% of its workforce uses its proprietary AI platform, which applies large language models to automate and simplify processes. An enterprise-wide training program teaches employees to use generative and agentic AI responsibly.

Gemini Enterprise is next, for everyone. Williams said Merck has “a roadmap and a deployment plan for Gemini Enterprise across all our employees.” Google Cloud engineers work alongside Merck teams on the rollout.
Adoption is uneven, and Merck plans for that. Williams described early adopters, a middle group that needs more time and employees who are “absolutely petrified.” His advice is to bring in tools “just one at a time,” which is core to AI change management.
Governance relies on human review. Medical writers oversee every AI-drafted clinical study report, and AI-made content passes medical, legal and regulatory review. Williams describes the approach as enabling teams “with the appropriate safeguards,” and Merck has published no AI governance framework.
Merck is also cutting costs. In July 2025, Merck began a program that targets about $3 billion in annual savings by the end of 2027, with some administrative, sales and research roles cut (PharmExec). Merck has not tied the cuts to AI, and headcount held at about 75,000 in 2025.
AI fluency, coded against the Lead with AI Fluency Matrix (September 2026 edition):
- Fluency floor: Not published. More than 80% of the workforce uses Merck’s AI platform and training is offered company-wide, but Merck has set no required level for all staff.
- Highest level evidenced: Level 3 (Integrating), company-claimed. Merck rebuilt clinical study report writing around its generative AI platform, with medical writers reviewing every draft. The results have not been independently verified.
- Portfolio design: Merck runs five CEO-sponsored programs across its value chain, from discovery to corporate functions, on one partner platform.
How Merck Measures Results
Merck reports results by use case. All figures below are company-claimed:
- Medical writing: first drafts of clinical study reports in three to four days instead of two to three weeks, review time down from 180 hours to 80 and errors down 50% (Merck, June 2025)
- Drug discovery: at least 30% higher productivity from in silico methods over the past couple of years, a figure Williams calls conservative
- Manufacturing: supply chain risk assessments produced in under 30 minutes
Gaps remain. Merck gives no company-wide value figure for AI, and it has not linked AI to its $3 billion savings target. Connecting use-case results to cost and growth is the step from AI adoption to AI value.
Next markers: results from the Google Cloud agents, a value figure for AI, progress on the $3 billion savings program and headcount for 2026.
Change log
- June 2025: Merck reports faster clinical study reports from its generative AI platform.
- July 2025: Merck announces a program to save about $3 billion a year by the end of 2027.
- January 2026: Merck says more than 80% of its workforce uses its AI platform.
- April 2026: Merck and Google Cloud announce an agentic AI partnership worth up to $1 billion.
- September 2026: Gaurav Gupta becomes Chief Information and Digital Officer.
The Bottom Line
- Disclosure: 4 of 4. Merck answers all four questions, and it measures results by use case without a total.
- One partner supports five programs. Google Cloud backs CEO-sponsored programs from discovery to corporate functions.
- Use is broad, with more than 80% of the workforce on Merck’s AI platform.
- Level 3 is evidenced in medical writing, on company-claimed results.
- The say-do gap is value. Merck reports strong use-case results but no total and no link to its savings program.
- Watch the agents. The test is whether the Google Cloud platform delivers results Merck can count across functions.
Revenue, Headcount and Revenue per Employee
What the numbers show: Revenue rose 10% from 2022 to 2025 while headcount rose 9%, so revenue per employee was roughly flat, at about $867,000. Headcount held at about 75,000 in 2025, the year Merck began a cost program that targets about $3 billion in annual savings by the end of 2027. These figures do not show that AI caused any change.
Revenue, headcount and revenue per employee, FY2022 to FY2025
- FY2022: $59.28bn revenue, 69,000 employees, $859k per employee
- FY2023: $60.12bn revenue, 72,000 employees, $835k per employee
- FY2024: $64.17bn revenue, 75,000 employees, $856k per employee
- FY2025: $65.01bn revenue, 75,000 employees, $867k per employee
Change, FY2022 to FY2025: revenue up 10%, headcount up 9%, revenue per employee up 1%.
Notes: Revenue is total sales, as reported. Headcount is approximate, at December 31. Merck began a cost program in July 2025 that targets about $3 billion in annual savings by the end of 2027, with some administrative, sales and research roles cut.
These figures give context on scale and productivity. They do not show that AI caused any change. Sources: Merck 10-K filings.
How Merck Compares with US Pharma Peers
We looked at how Merck compares with other US pharmaceutical companies in the index. Here is how they stack up.
| Company | Disclosure | AI owner | Fluency floor | Governance | AI value reported | Revenue per employee |
|---|---|---|---|---|---|---|
| AbbVie | 4 of 4 | VP of AI Strategy and Partnerships | Not published; training offered at all levels | Human expertise and ethical use; no published framework | One result (regulatory writing), no total | $1.07M |
| Amgen | 3 of 4 | EVP of research, AI and data; SVP and CTO | Not published; ChatGPT Enterprise across the company | Published AI Vision; phased rollouts | None published | $1.17M |
| Bristol Myers Squibb | 4 of 4 | EVP and Chief Digital and Technology Officer | Not published; frontier models for all staff | Enterprise governance and audit controls; humans decide | Targets set, no results | $1.48M |
| Eli Lilly | 3 of 4 | Chief AI Officer | Level 1, by expectation | Eight principles, board briefings | No: capacity and deals | $1.30M |
| Gilead Sciences | 2 of 4 | Global CIO; no AI leader named | Not published; AI coach in pilot | Six published AI principles | None published | $1.73M |
| Johnson & Johnson | 4 of 4 | EVP and CIO; each function governs its own AI | Level 1, training required before access (2024) | Function-led governance; central AI board removed | Results by use case, no total | $682k |
| Merck | 4 of 4 | CEO sponsors five AI programs; CIO leads technology | Not published; 80%+ use the AI platform | Human review of AI drafts; no published framework | Results by use case, no total | $867k |
| Pfizer | 3 of 4 | Chief AI, Data and Analytics Officer | Level 1, 98% trained | Three principles, a board risk topic | Inside wider cost programs | $834k |
| Moderna AI Pacesetter | 2 of 4 | Chief People and Digital Technology Officer | Level 1, by expectation | Mentioned, not described | No: adoption figures | $414k |
Disclosure counts how many of the four strategy questions (where it is going, where it will focus, what it will take and how it will know it is working) a company answers in public. Fluency floor is the lowest level of AI fluency a company expects of all its people, on the five levels of the Lead with AI Fluency Matrix: Avoiding (0), Chatting (1), Collaborating (2), Integrating (3) and Transforming (4). The other columns summarize each company’s profile. Revenue per employee is for each company’s latest fiscal year, in US dollars. Rows marked AI Pacesetter or Notable are companies outside the S&P 100 and STOXX Europe 50. They are shown for contrast and are not counted in any index figure. See all companies in the AI Strategy Index.
Frequently Asked Questions
What is Merck’s AI strategy for its own work?
Merck is rolling out AI agents across research, manufacturing, commercial and corporate functions, in a Google Cloud partnership worth up to $1 billion. Five lighthouse programs, sponsored by the CEO, set the focus.
Who leads AI at Merck?
Chairman and CEO Rob Davis sponsors Merck’s five AI lighthouse programs. Gaurav Gupta, Executive Vice President and Chief Information and Digital Officer since September 2026, leads technology.
How many Merck employees use AI?
Merck says more than 80% of its workforce uses its proprietary AI platform. It plans to roll out Gemini Enterprise to all employees.
Is Merck cutting jobs because of AI?
Merck has not linked job cuts to AI. Its cost program, begun in July 2025, cuts some administrative, sales and research roles, and headcount held at about 75,000 in 2025.
How is this profile put together?
Lead with AI profiles use public sources only, such as annual reports, earnings materials, filings and on-record interviews, dated at the time of writing. AI fluency is coded against the Lead with AI Fluency Matrix, and company figures are marked as company-claimed unless they have been independently verified.
About the AI Strategy Index
The Lead with AI AI Strategy Index profiles how the largest companies in the US and Europe approach AI, starting with the S&P 100 and the STOXX Europe 50. Each profile answers four questions: where the company is going with AI, where it will focus, what it will take and how it will know it is working. AI Pacesetters and notable companies outside the two indexes are profiled for contrast and are not counted. Profiles use public sources only, and AI fluency is coded against the Lead with AI Fluency Matrix.
See all company profiles